CABOTEGRAVIR/LENACAPAVIR DUAL LONG ACTING THERAPY (COHORT IMEA 074)

Starting soon

Conditions studied: CABOTEGRAVIR, LENACAPAVIR

In brief

The main objective of this national study is to evaluate the virological success of long-acting antiretroviral therapy combining cabotegravir and lenacapavir. The study involves patients who have been receiving this treatment for one year or those for whom the physician decides to initiate it. It also aims to evaluate the tolerability of the treatment and changes in the participants' immunovirological profile during follow-up.

Key facts

Study ID

NCT07402044

Run by

Institut de Médecine et d'Epidémiologie Appliquée - Fondation Internationale Léon M'Ba

People needed

50

Starts

2026-03-15

Expected to finish

2028-03-15

Last updated by the study team

2026-03-27

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may not qualify if…

• Participants' objection to the use of follow-up data

Where it is running

• Victor Dupuy Hospital — Argenteuil, France
• Pellegrin Hospital — Bordeaux, France
• Saint André Hospital — Bordeaux, France
• Raymond poincaré Hospital — Garches, France
• Franco-British Hospital (Fbh) — Levallois-Perret, France
• Hotel Dieu Hospital — Nantes, France
• Archet 1Hospital — Nice, France
• Bichat Claude Bernard Hospital — Paris, France
• Hotel Dieu Hospital — Paris, France
• Necker Hospital — Paris, France
• Pitié Salpêtrière Hospital — Paris, France
• Saint Antoine Hospital — Paris, France
• Tourcoing Hospital — Tourcoing, France

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.